# The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

> **NCT04329728** · PHASE1,PHASE2 · RECRUITING · sponsor: **AVM Biotechnology Inc** · enrollment: 144 (estimated)

## Conditions studied

- Lymphoid Malignancies

## Interventions

- **DRUG:** AVM0703

## Key facts

- **NCT ID:** NCT04329728
- **Lead sponsor:** AVM Biotechnology Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-11-06
- **Primary completion:** 2027-11-30
- **Final completion:** 2028-12-01
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04329728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04329728, "The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04329728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*